MDMA induced dopamine release in vivo: Role of endogenous serotonin

Journal of Neural Transmission

Volumn 104, Issue 2-3, 1997, Pages 135-146

  Koch, S ^a   Galloway, M P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain slices; Dopamine serotonin; MDMA; Microdialysis; Striatum

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; FLUOXETINE; SEROTONIN; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030909052     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01273176     Document Type: Article

References (48)

1. Battaglia G, Sharkey J, Kuhar MJ, De Souza EB (1991) Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography. Synapse 8: 249-260
2. Bel N, Artigas F (1992) Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 229: 101-103
3. Benloucif SB, Galloway MP (1991) Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 200: 1-8
4. Benloucif SB, Keegan MJ, Galloway MP (1993) Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 265: 373-377
5. Bradberry CW (1994) Microdialysis assessment of the impact of (+)3,4-methylenedioxymethamphetamine, cocaine, and cocaethylene on serotonergic neurons. Drug Dev Res 33: 1-9
6. Brodkin J, Malyala A, Nash JF (1993) Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 45: 647-653
7. Cass WC, Gerhardt GA (1994) Direct in vivo evidence that D2 receptors can modulate dopamine uptake. Neurosci Lett 176: 259-263
8. 3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse 10: 264-266
9. Clark D, Salah RS, Galloway MP (1991) Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine. Synapse 8: 169-176
10. Galloway MP (1996) Augmentation of selective serotonin reuptake inhibitor antidepressant efficacy with pindolol and the relevance of 5-HT1A autoreceptors. Anxiety 2: 149-152
11. Galloway MP, Wolf ME, Roth RH (1986) Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo. J Pharmacol Exp Ther 236: 689-698
12. Galloway MP, Suchowski CS, Keegan MJ, Hjorth S (1993) Local infusion of the selective 5-HT-1b agonist CP-93,129 facilitates striatal dopamine release in vivo. Synapse 15: 90-92
13. Gough B, Ali SF, Slikker Jr W, Hoson RR (1991) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 39: 619-623
14. Hekmatpanah CR, Peroutka SJ (1990) 5-Hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxy-methamphetamine and related agents. Eur J Pharmacol 177: 95-98
15. Hiramatsu M, Cho AK (1990) Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striaturn of freely-moving rats: an in vivo microdialysis study. Neuropharmacology 29: 269-275
16. 2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol 238: 291-296
17. Iyer RN, Bradberry CW (1996) Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 277: 40-47
18. Malagie I, Trillat A-C, Jacquot C, Gardier AM (1995) Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. Eur J Pharmacol 286: 213-217
19. McCann UD, Ricaurte GA (1993) Reinforcing subjective effects of (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence. J Clin Psychopharmacol 13: 214-217
20. McKenna DJ, Peroutka J (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J Neurochem 54: 14-22
21. 2 receptors may modulate the function of striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 61: 764-767
22. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 600: 640-661
23. Nash JF (1990) Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 47: 2401-2408
24. Nash JF, Yamamoto BK (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymeth-amphetamine. Brain Res 581: 237-243
25. Nash JF, Meltzer HY, Gudelsky GA (1990) Effects of 3,4-methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens. J Neurochem 54: 1062-1067
26. Parsons LH, Justice JB Jr (1993) Perfusate serotonin increases extracellular dopamine in the nuceus accumbens as measured by in vivo microdialysis. Brain Res 606: 195-199
27. 2 antagonist pimozide inhibits up-regulation of dopamine release and uptake induced by repeated cocaine. J Neurochem 60: 376-379
28. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, New York
29. Peroutka SJ (1987) Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy") on an undergraduate campus. N Engl J Med 317: 1542-1543
30. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharm 1: 273-277
31. Ricaurte GA (1989) Studies of MDMA-induced neurotoxicity in nonhuman primates: a basis for evaluating long-term effects in humans. NIDA Res Monogr 94: 306-322
32. Ricaurte GA, DeLanney LE, Irwin I, Langston JW (1988) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 446: 165-168
33. Ricaurte GA, Martello AL, Katz JL, Martello MB (1992) Lasting effects of (±)-3,4-methylendioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261: 616-622
34. Robinson TE, Whishaw IQ (1988) Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 450: 209-224
35. Rudnick G, Wall SC (1991) The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced sertotonin release. Proc Natl Acad Sci 89: 1817-1821
36. Rutter JJ, Auerbach SB (1993) Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J Pharmacol Exp Ther 265: 1319-1324
37. Schmidt CJ, Taylor VL (1988) Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. Eur J Pharmacol 156: 121-131
38. Schmidt CJ, Taylor VL (1990) Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhititors. Eur J Pharmacol 181: 133-136
39. 2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 255: 478-483
40. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. J Pharmacol Exp Ther 256: 230-235
41. 2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 223: 65-74
42. Stone DM, Merchant KM, Hanson GR, Gibb JVV (1987) Immediate and long-term effects of 3,4-methylenedioxymeth-amphetamine on serotonin pathways in the brain of rat. Neuropharmacology 26: 1677-1683
43. Stone DM, Johnson M, Hanson GR, Gibb JW (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetame. J Pharmacol Exp Ther 247: 79-87
44. Tanda G, Bassareo V, Di Chiara G (1996) Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat. Psychopharmacol 123: 127-130
45. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacol 98: 45-50
46. West AR, Galloway MP (1996) Regulation of serotonin-facilitated dopamine release in vivo: the role of protein kinase A activating transduction mechanisms. Synapse 23: 20-27
47. Yadid G, Cak K, Kopin IJ, Goldstein DS (1994) Endogenous serotonin stimulates striatal dopamine release in conscious rats. J Pharmacol Exp Ther 270: 1158-1165
48. Yamamoto BK, Spanos LJ (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 148: 195-203